Iovance Biotherapeutics to Present at the Jefferies 2017 London Healthcare Conference
November 13 2017 - 08:00AM
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
that Chief Financial Officer, Timothy Morris, will present a
Company overview and pipeline update at the Jefferies 2017
London Healthcare Conference on Thursday, November 16, 2017 at
10:00 a.m. GMT in London, United Kingdom.
A live audio webcast of the presentation will be available by
visiting the Investors section of Iovance Biotherapeutics' website
at http://ir.iovance.com/. A replay of the webcast will be
archived on Iovance Biotherapeutics’ website for 30 days following
the presentation.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage
biotechnology company focused on the development of cancer
immunotherapy products for the treatment of various cancers. The
Company's lead product candidate is an adoptive cell therapy using
tumor-infiltrating lymphocyte (TIL) technology being investigated
for the treatment of patients with metastatic melanoma, recurrent
and/or metastatic squamous cell carcinoma of the head and neck and
recurrent and metastatic or persistent cervical cancer. For more
information, please visit http://www.iovance.com.
Investor Relations Contact: Sarah McCabeStern
Investor Relations, Inc.212-362-1200sarah@sternir.com
Media Relations Contact:Evan Smith/Kotaro
YoshidaFTI Consulting212-850-5622/212-850-5690
evan.smith@fticonsulting.com kotaro.yoshida@fticonsulting.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2023 to Mar 2024